EP0658106A1 - Derives de thiol de maintien et/ou d'augmentation de la force musculaire et de la masse de cellules du corps - Google Patents

Derives de thiol de maintien et/ou d'augmentation de la force musculaire et de la masse de cellules du corps

Info

Publication number
EP0658106A1
EP0658106A1 EP93919231A EP93919231A EP0658106A1 EP 0658106 A1 EP0658106 A1 EP 0658106A1 EP 93919231 A EP93919231 A EP 93919231A EP 93919231 A EP93919231 A EP 93919231A EP 0658106 A1 EP0658106 A1 EP 0658106A1
Authority
EP
European Patent Office
Prior art keywords
composition according
cell mass
cysteine
body cell
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93919231A
Other languages
German (de)
English (en)
Inventor
Wulf DRÖGE
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of EP0658106A1 publication Critical patent/EP0658106A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to an agent for maintaining and / or increasing muscle performance and body cell mass.
  • the agent contains a thiol compound, in particular cysteine, a derivative and / or analogue thereof, and customary auxiliaries.
  • the muscle mass of a body has an influence not only on muscle performance, but also on the entire protein metabolism of the body.
  • the massive loss of muscle mass and the associated reduction in body cell mass and the body's most important amino acid reservoir is a common and life-threatening complication in cancer and infectious diseases, such as the immune deficiency AIDS.
  • older people show a progressive loss of skeletal muscle mass and muscle performance. This is associated with diverse and constantly increasing complaints, ranging from muscle strains, spinal damage to age-related physical deterioration and acute need for care.
  • the cachectic processes are generally perceived as particularly stressful by the patients.
  • the object of the present invention is therefore to provide a preparation with which the above-mentioned complaints can be successfully treated.
  • this is done by providing an agent achieved that contains a thiol compound, in particular cysteine, a derivative and / or analogue thereof, and conventional auxiliaries.
  • a thiol compound in particular cysteine, a derivative and / or analogue thereof, and conventional auxiliaries.
  • Glutathione can also be mentioned as a favorable thiol compound.
  • N-acetyl cysteine and homocysteine and a thiazolidine derivative of cysteine, for example 2-oxo-4-thiazolidine carboxylate, are also particularly suitable.
  • the agent according to the invention has a substance which improves the uptake of the active compound (s) by the cell.
  • Common substances can be used for this purpose, which facilitate the transport of substances into the cell.
  • Liposomes are preferably used, in the lumen of which the active compound (s) are incorporated. Liposomes are produced by the customary methods described in the literature.
  • the agent according to the invention has a substance which increases the activity of the active compound (s).
  • a substance is, for example, a hormone, such as insulin or insulin-like growth factor, a vitamin, a nutrient, such as glucose or an amino acid, or a common muscle-building medication, such as an anabolic steroid.
  • the agent according to the invention expediently contains 5-95, preferably 30-70 and in particular 40-60% by weight of active compound or active compounds and 95-5, preferably 70-30 and in particular 60-30% by weight of customary auxiliaries .
  • the agent can be applied in the usual ways, such as orally, parenterally or locally, with oral application being preferred.
  • the agent can be applied in customary forms, such as a solution, suspension, emulsion, powder, tablet, capsule or ointment, gastric juice-resistant capsules being preferred.
  • the usual additives such as
  • Drug carriers binders, disintegrants, lubricants,
  • Release delays, emulsifiers, stabilizers e.g.
  • Antioxidants, buffers), colorants or flavoring agents can be used.
  • the solvent is pyrogen-free water or physiological saline
  • the dosage of the agent according to the invention is advantageously 50 mg - 5 g, preferably 200 mg - 4 g and in particular 2 x 200 mg of active compound (s) per day.
  • a different dosage may be required in individual cases and can easily be determined by a person skilled in the art.
  • the agent according to the invention makes it possible to maintain and / or increase the muscle performance and body cell mass of a human as well as an animal body, regardless of whether it is sick or healthy. It is suitable for the treatment of cachectic processes that occur as a complication in cancer and infectious diseases, such as AIDS, and also in old age. It is also suitable to be used for muscle injuries such as strains and tears. In addition, it should also be pointed out that it can be used in healthy people, as a result of which muscle strengthening and thus increased performance can be achieved.
  • N-acetyl-cysteine was administered to 13 healthy males between the ages of 20 and 60 years for 4 weeks in a dose of 2 x 200 mg 3 times a week.
  • the study was randomized and double-blind with an equal number of PLazebo controls.
  • the test subjects carried out an extensive sports program with a defined, essentially anaerobic load, in particular on the arm muscles.
  • the muscle strength and the local-venous lactate concentration in the cubital vein were measured at different times after completing standardized muscle training (handgrip tests) (Sinkeier et al., Muscle & Nerve (1985), pp. 523-527) .
  • the drop in lactate concentration after exercise served as a measure of the aerobic capacity of the stressed muscles.
  • the results in FIG. 1 show the quotients of the lactate values at the end of the study compared to the corresponding lactate values at the beginning of the study. These quotients are a measure of the change in aerobic performance during the 4-week anaerobic exercise program, i.e. a quotient of over 1 means a deterioration in aerobic performance.
  • the results of the study show that the muscle strength had improved slightly on average in both the experimental and the placebo group through the training program (data not shown); the aerobic capacity in the
  • the placebo group had deteriorated significantly since the lactate values 10 minutes after exercise were significantly higher at the end of the 4-week study than at the beginning of the study.
  • the recovery of the muscles from the strongly glycolytic state was worse at the end of the study than at the beginning of the study.
  • the muscle training in the untreated normal people was accordingly not only of the positive effect of the training-related increase in muscle strength, but also of negative effects on certain biochemical performances of the
  • AIDS patients and cachectic cancer patients often have elevated plasma triglyceride and plasma glutamate levels. Healthy people sometimes show this too. Episodes with a relatively sharp drop in body cell mass and a simultaneous build-up of body fat then occur in them. This is evident from the applicant's recent work.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Un produit de maintien et/ou d'augmentation de la force musculaire et de la masse de cellules du corps contient un composé de thiol, notamment la cystéine, un dérivé et/ou un analogue de celui-ci et des additifs usuels.
EP93919231A 1992-09-01 1993-08-31 Derives de thiol de maintien et/ou d'augmentation de la force musculaire et de la masse de cellules du corps Withdrawn EP0658106A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4229166 1992-09-01
DE4229166A DE4229166A1 (de) 1992-09-01 1992-09-01 Mittel zur Aufrechterhaltung und/oder Steigerung der Muskelleistung und Körperzellmasse
PCT/EP1993/002354 WO1994005270A1 (fr) 1992-09-01 1993-08-31 Derives de thiol de maintien et/ou d'augmentation de la force musculaire et de la masse de cellules du corps

Publications (1)

Publication Number Publication Date
EP0658106A1 true EP0658106A1 (fr) 1995-06-21

Family

ID=6466977

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93919231A Withdrawn EP0658106A1 (fr) 1992-09-01 1993-08-31 Derives de thiol de maintien et/ou d'augmentation de la force musculaire et de la masse de cellules du corps

Country Status (7)

Country Link
US (1) US5744157A (fr)
EP (1) EP0658106A1 (fr)
JP (1) JPH08500602A (fr)
DE (1) DE4229166A1 (fr)
MX (1) MX9305350A (fr)
WO (1) WO1994005270A1 (fr)
ZA (1) ZA936283B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030203006A1 (en) * 1997-10-29 2003-10-30 Ajinomoto Co. Inc. Immunomodulator
US7045532B2 (en) * 1999-04-30 2006-05-16 Millennium Pharmaceuticals, Inc. ACE-2 modulating compounds and methods of use thereof
JP2003511094A (ja) * 1999-10-18 2003-03-25 マッスルテク リサーチ アンド ディヴェロプメント インコーポレーション 無脂肪体重及び体力を増強するための食物補充物質
US6784209B1 (en) * 1999-10-18 2004-08-31 Muscletech Research And Development Inc. Food supplement for increasing lean mass and strength
DE10162840A1 (de) * 2001-12-20 2003-07-03 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an wasserlöslichen UV-Filtersubstanzen und Benzoxazol-Derivaten
US20050238654A1 (en) * 2004-04-26 2005-10-27 Yoshinori Takeda Compositions and methods for weight loss
JP2009001507A (ja) * 2007-06-19 2009-01-08 Ss Pharmaceut Co Ltd 体脂肪減少剤およびその利用
EP2444083A1 (fr) * 2010-10-21 2012-04-25 Nestec S.A. Cystéine et ingestion d'aliments
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
PE20200747A1 (es) 2017-08-14 2020-07-24 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica
AR115585A1 (es) 2018-06-20 2021-02-03 Axcella Health Inc Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1666M (fr) * 1961-11-27 1963-01-21 Commerce Ind Africain C I A
DE3906671A1 (de) * 1989-03-02 1990-09-06 Wulf Prof Dr Droege Orales, magenvertraegliches n-acetylcysteinpraeparat hoher dosierung
US5292773A (en) * 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9405270A1 *

Also Published As

Publication number Publication date
WO1994005270A1 (fr) 1994-03-17
US5744157A (en) 1998-04-28
MX9305350A (es) 1994-04-29
JPH08500602A (ja) 1996-01-23
ZA936283B (en) 1994-03-21
DE4229166A1 (de) 1994-03-03

Similar Documents

Publication Publication Date Title
DE69533940T2 (de) Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren
EP0357978B1 (fr) Préparation pharmaceutique pour le traitement du diabète sucré
EP0203580B1 (fr) Gamma-IFN comme agent d'inhibition (d'empêchement) de processus de décomposition des os
DE69432905T2 (de) Verwendung von ketoconazol und verwandten substanzen in medikamenten für die behandlung des typ ii-diabetes
CH653891A5 (de) Mittel fuer die orale verabreichung an einen menschen und/oder ein saeugetier.
DE3005208A1 (de) Verwendung von acylcarnitin in arzneimitteln zur behandlung von stoerungen im gehirn-metabolismus
DE3247062A1 (de) Verwendung eines chelatbildners als arzneimittel zur behandlung der alzheimer-krankheit
EP0658106A1 (fr) Derives de thiol de maintien et/ou d'augmentation de la force musculaire et de la masse de cellules du corps
DE69821498T2 (de) Verwendung von amifostin
DE3115080C2 (de) Arzneimittel enthaltend Cytidindiphosphocholin und Lecithin
EP1978995A1 (fr) Procede de traitement et/ou de prophylaxie de la sclerose en plaques et utilisation d'erythropoietine pour la fabrication d un medicament pour le traitement intermittent et/ou la prophylaxie intermittente de la sclerose en plaques
AT397200B (de) Verwendung von selenmethionin zur herstellung eines arzneimittels
DE60206169T2 (de) Kombination enthaltend einen p-gp hemmer und einen antiepileptischen wirkstoff
EP0013962B1 (fr) Solution d'infusion contenant des acides amino et des sels minéraux
DE2633891C2 (de) Tris-(hydroxymethyl)-aminomethansalz der 2-(5-Benzoylthienyl)-α-methylessigsäure, Verfahren zu dessen Herstellung und dieses enthaltende pharmazeutische Zusammensetzungen
DE602005005454T2 (de) Behandlung von Einschlusskörper-Myositis
DE4329857C2 (de) Verbindung zur Stärkung des Immunsystems und von Immunreaktionen
DE19636252C2 (de) Pharmazeutisches Kombinationspräparat zur Behandlung von rheumatischen Erkrankungen
AT408719B (de) Mittel zur behandlung von hepatitis c
DE4406261C2 (de) Verwendung von Thiolverbindungen zur Verminderung der Körperfettmenge
DE2117762A1 (de) Behandlung von Alopecia und pharmazeutische Präparation für die Durchführung der Behandlung
WO1996033707A1 (fr) Preparation topique pour favoriser le developpement musculaire
EP0297630A1 (fr) Médicament contenant des anesthésiques locaux et des nucléosides
EP2548564B1 (fr) Produit pharmaceutique, alimentation d'un patient et procédé de réduction du poids
EP1528922B1 (fr) Utilisation de treosulfan et de ses derives pour traiter la sclerose en plaques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950303

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19980202

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DROEGE, WULF

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DROEGE, WULF

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020301